Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Wave Life Sciences Ltd.NASDAQ: WVE

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $47.44M rose 16.8% year over year, ahead of the +13.6% change in trailing-twelve-month research & development. Sequentially, it fell 10.2% from the prior quarter. Over 3 fiscal years it compounded at +16.4% a year.

Context

  • Research & development amounted to 427.8% of revenue in FY2025, up 280.3 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +16.8% holds above the trailing-twelve-month pace of +13.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$47.44M-10.2% QoQ
Last fiscal yearDec 2025
$182.78M+14.5% YoY
LTMMar 2026
$189.6M+13.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.8%——
1 year+14.5%——
3-year CAGR+16.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
182.78M USD
Year-over-year change
+14.5%
4-year CAGR
+10.7%

Research & Development vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.6% is the 4th highest of 10, against a peer median of +4.7%.
  • Research & development amounts to 264.1% of revenue for WVE, versus a peer median of 216.6%.
WVE Competitors
Research & Development for WVE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.51B USD+30.1%+14.5%31.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$923.16M USD+4.7%+3.2%96.2%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$902.58M USD-34.5%+20.2%41.3%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$739.14M USD+21.7%+29.3%164.0%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$361.17M USD-21.5%-2.5%546.5%
WVEWave Life Sciences Ltd.LTM Mar 2026$189.6M USD+13.6%+16.4%264.1%
STOKStoke Therapeutics, Inc.LTM Mar 2026$144.07M USD+45.7%+21.0%449.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$98.25M USD-44.3%-8.8%216.6%
SLNSilence Therapeutics plcLTM Mar 2026$61.84M USD—+24.0%6710.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026€44.34M EUR+12.6%-7.1%329.9%
BNTCBenitec Biopharma Inc.LTM Mar 2026$19.2M USD+1.2%+17.6%—
Peer median (excluding WVE) —+4.7%+16.0%216.6%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.96M3.65M113.31M108.3M42.73M
Cost of Revenue00008.85M
Gross Profit40.96M3.65M113.31M108.3M33.88M
Gross Margin100.0%100.0%100.0%100.0%79.3%
Research & Development121.88M115.86M130.01M159.68M182.78M
Selling, General & Admin46.11M50.51M51.29M59.02M75.33M
Operating Expenses167.98M166.37M181.3M218.71M249.26M
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
EBITDA(112.61M)(151.03M)(48.98M)(88.35M)(195.53M)
EBITDA Margin-274.9%-4138.9%-43.2%-81.6%-457.6%
Operating Income(127.02M)(162.72M)(68M)(110.4M)(215.38M)
Operating Margin-310.1%-4459.3%-60.0%-101.9%-504.1%
Interest Income30K00010.48M
Interest Expense00000
Other Income / Expenses4.57M1.58M9.81M13.4M11.01M
Income Before Tax(122.45M)(161.14M)(58.19M)(97.01M)(204.38M)
Pre-Tax Margin-298.9%-4416.1%-51.4%-89.6%-478.3%
Income Tax Expense(204K)681K(677K)00
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (Basic)(2.36)(2.05)(0.54)(0.70)(1.21)
EPS (Diluted)(2.36)(2.05)(0.54)(0.70)(1.21)
Weighted Avg Shares51.83M78.86M106.1M138.28M168.65M
Weighted Avg Shares (Diluted)51.83M78.86M106.1M138.28M168.65M

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.